Harmony Biosciences (HRMY) Tops Q1 EPS by 42c, provides guidance

Harmony Biosciences (NASDAQ: HRMY) reported Q1 EPS of $1.03, $0.42 better than the analyst estimate of $0.61. Revenue for the quarter came in at $184.7 million versus the consensus estimate of $184.26 million.

GUIDANCE:

Harmony Biosciences sees FY2025 revenue of $820-860 million, versus the consensus of $840.4 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Assembly Biosciences (ASMB) Tops Q2 EPS by 53c
• KULR Technology Group (KULR) Misses Q2 EPS by 39c